Susquehanna International Group, LLP Ventyx Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.85 - $3.2 $336,145 - $581,440	-181,700 Reduced 94.78%	10,000 $21,000
Q2 2024 Aug 15, 2024	BUY	$2.31 - $5.59 $107,646 - $260,494	46,600 Added 32.12%	191,700 $442,000
Q1 2024 May 07, 2024	BUY	$1.9 - $10.13 $137,940 - $735,438	72,600 Added 100.14%	145,100 $798,000
Q4 2023 Feb 14, 2024	SELL	$2.08 - $31.18 $100,464 - $1.51 Million	-48,300 Reduced 39.98%	72,500 $179,000
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $2.55 Million - $3.45 Million	85,500 Added 242.21%	120,800 $4.2 Million
Q2 2023 Aug 11, 2023	SELL	$28.53 - $39.55 $1.2 Million - $1.66 Million	-41,900 Reduced 54.27%	35,300 $1.16 Million
Q1 2023 May 16, 2023	BUY	$29.51 - $46.65 $2.28 Million - $3.6 Million	77,200 New	77,200 $2.59 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $333,696 - $1.02 Million	26,400 New	26,400 $922,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.